Previous close | 44.11 |
Open | 44.10 |
Bid | 44.17 x 100 |
Ask | 44.39 x 100 |
Day's range | 43.81 - 44.80 |
52-week range | 31.52 - 54.98 |
Volume | |
Avg. volume | 735,090 |
Market cap | 3.638B |
Beta (5Y monthly) | 0.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
In this article, we discuss the 10 NASDAQ stocks with the biggest upside. To skip our detailed analysis, go directly to the 5 NASDAQ Stocks with Biggest Upside. The Nasdaq Composite was the worst performer among the major market indices in 2022 and made a stellar comeback in 2023. The index was down 33% at […]
Thomas Kassberg, the Chief Business Officer and Executive Vice President of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), has sold 11,509 shares of the company on March 11, 2024, according to a recent SEC filing.